Home Biological science Nodexus Inc. exits Stealth with $ 30 million Series A funding to advance manufacturing and expand marketability of NX One platform

Nodexus Inc. exits Stealth with $ 30 million Series A funding to advance manufacturing and expand marketability of NX One platform

0


The NX One platform is the first universally adoptable system for characterizing, sorting and isolate single cells from biological samples

Industry veteran William Rhodes joins board

SAN JOSE, Calif .– (BUSINESS WIRE) – Nodexus Inc., an emerging leader in the development of automated live cell characterization and isolation technologies, has raised $ 30 million in oversubscribed Series A funding that will allow the company to expand the manufacturing of its flagship NX One platform as well as expand its marketing capabilities and pipeline to meet growing demand. The funding was led by RA Capital Management with participation from Section 32 as well as former investors. The company also announced the appointment of William Rhodes to the board of directors.

“Flow cytometry and cell sorting are extremely valuable techniques that can help researchers in the life sciences and health sectors unlock new biological discoveries, but only if they have access to these tools. The NX One system provides automated sorting and distribution of single usable cells at an unprecedented affordable price to allow deployment in virtually any laboratory working in gene editing, cancer biology research, bioprocessing and other rapidly growing applications, ”said Karthik Balakrishnan, PhD, Founder and CEO of Nodexus. “We are excited to provide a widely available solution for customers ranging from startups and academic labs to larger life science companies. The funding announced today will allow us to significantly expand our team to support our mission to democratize biological tools. “

The analysis and isolation of single cells have become fundamental needs in scientific research. Cell sorting instruments are often limited to centralized facilities, as they generally require expert technicians for their operation and a significant investment in equipment. The patented NX One uses microfluidic technology in combination with a compact integrated system to provide affordable on-demand analysis, sorting and distribution of cells.

“We believe that the Nodexus platform will enable widespread access to single cells, accelerating biomedical innovation,” said Tess Cameron, principal at RA Capital and member of the board of directors of Nodexus. “We look forward to working closely with Nodexus as it expands its manufacturing capacity, sales capabilities and team to meet the growing demand for this technology. “

Along with the financing, William Rhodes was appointed to the company’s board of directors. Mr. Rhodes is a seasoned healthcare executive with extensive experience in the diagnostic tools and life sciences industries. During his sixteen-year career with Becton, Dickinson and Co. (BD), Mr. Rhodes served as Executive Vice President of Corporate Strategy and Development of BD and Global President of BD Biosciences, a business unit of BD. $ 1.4 billion which included cell analysis, discovery software and advanced software. Bioprocessing. Prior to BD, Mr. Rhodes held senior positions at Johnson & Johnson and Pfizer.

“The NX One system has the potential to transform life sciences and cell biology by making single-cell analysis and isolation much more accessible to laboratories and researchers around the world,” said Rhodes. “I am delighted to be working with the Nodexus team to help grow their business organization to meet the demand for this exciting and innovative platform. “

About Nodexus

Nodexus is a life science tools company that develops platforms to accelerate biological workflows and make them more widely accessible. The company relies on an exclusive technology suite made up of microfluidic cartridges, hardware instruments and software offerings. Nodexus’ flagship NX One platform provides integrated, easy-to-use and affordable automated cell isolation for applications in industry, clinical research and academia, including cell line and antibody development, l ‘CRISPR engineering, single-cell genomics, synthetic biology, etc. . For more information about the company, please visit Nodexus.